Agomab Starts Global Phase 2b Trial in FSCD Patients

Agomab dosed the first patient in the global randomized NOV-ERA study of ontunisertib, which plans to enroll about 320 FSCD patients. Endoscopic passability at Week 24 is the primary endpoint. The study start triggers a €7 million milestone tied to the Origo Biopharma acquisition.